Scilight Press

Author Information

Received: 28 Jan 2023 | Accepted: 27 Feb 2023 | Published: 20 Mar 2023

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

drug delivery | nanoparticles

References 

• 1.
  Canal P.; Gamelin E.; Vassal G.; et al. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Pathol. Oncol. Res., 1998, 4(3): 171-178.
• 2.
  Caliceti P.; Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Adv. Drug Delivery Rev., 2003, 55(10): 1261-1277.
• 3.
  Moghimi S.M.; Davis S.S. Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit. Rev. Ther. Drug Carrier Syst., 1994, 11(1): 31-59.
• 4.
  Accardo A.; Aloj L.; Aurilio M.; et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. Int. J. Nanomed., 2014, 9: 1537-1557.
• 5.
  Mendes R.; Fernandes A.R.; Baptista P.V. Gold nanoparticle approach to the selective delivery of gene silencing in cancer—the case for combined delivery? Genes, 2017, 8(3): 94.
• 6.
  Permana A.D.; Anjani Q.K.; Sartini.; et al. Selective delivery of silver nanoparticles for improved treatment of biofilm skin infection using bacteria-responsive microparticles loaded into dissolving microneedles. Mater. Sci. Eng.: C , 2021, 120: 111786.
• 7.
  Shi H.D.; Liu S.Z.; Cheng J.J.; et al. Charge-selective delivery of proteins using mesoporous silica nanoparticles fused with lipid bilayers. ACS Appl. Mater. Interfaces, 2019, 11(4): 3645-3653.
• 8.
  Oake A.; Bhatt P.; Pathak V.V. Understanding surface characteristics of nanoparticles. Pathak Y.V. Surface modification of nanoparticles for targeted drug delivery. Cham: Springer, 2019: 1-17.
• 9.
  Duan X.P.; Li Y.P. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small, 2013, 9(9/10): 1521-1532.
• 10.
  Jones M.; Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm., 1999, 48(2): 101-111.
• 11.
  Nishiyama N.; Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther., 2006, 112(3): 630-648.
• 12.
  Aghebati-Maleki A.; Dolati S.; Ahmadi M.; et al. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J. Cell. Physiol., 2020, 235(3): 1962-1972.
• 13.
  Gavas S.; Quazi S.; Karpiński T.M. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res. Lett., 2021, 16(1): 173.
• 14.
  Alshawwa S.Z.; Kassem A.A.; Farid R.M.; et al. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics, 2022, 14(4): 883.
• 15.
  Bhatia S. Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. Bhatia S. Natural polymer drug delivery systems. Cham: Springer, 2016: 33-93.
• 16.
  Patra J.K.; Das G.; Fraceto L.F.; et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol., 2018, 16(1): 71.
• 17.
  Aithal A.; Aithal P.S. The concept of ideal drug & its realization opportunity using nano pharmaceutical research scenario. International Journal of Health Sciences and Pharmacy, 2018, 2(2): 11-26.
• 18.
  LaVan D.A.; McGuire T.; Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol., 2003, 21(10): 1184-1191.
• 19.
  Ruiz M.E.; Scioli Montoto S. Routes of drug administration. Talevi A.; Quiroga P.A.M. ADME processes in pharmaceutical sciences: dosage, design, and pharmacotherapy success. Cham: Springer, 2018: 97-133.
• 20.
  Allen T.M.; Cullis P.R. Drug delivery systems: entering the mainstream. Science, 2004, 303(5665): 1818-1822.
• 21.
  Zunhammer M.; Ploner M.; Engelbrecht C.; et al. The effects of treatment failure generalize across different routes of drug administration. Sci. Transl. Med., 2017, 9(393): eaal2999.
• 22.
  Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. department of health and human services, Centers for Disease Control and Prevention, 2011.
• 23.
  Kadian R.; Nanda A. A comprehensive insight on recent advancements in self-emulsifying drug delivery systems. Curr. Drug Delivery. 2022, in press.
• 24.
  Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer, 2005, 5(3): 161-171.
• 25.
  Amiji M.M. Nanotechnology for cancer therapy. Boca Raton: CRC Press, 2006.
• 26.
  Riehemann K.; Schneider S.W.; Luger T.A.; et al. Nanomedicine--challenge and perspectives. Angew. Chem., Int. Ed. Engl., 2009, 48(5): 872-897.
• 27.
  Hashizume H.; Baluk P.; Morikawa S.; et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156(4): 1363-1380.
• 28.
  Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul., 2001, 41: 189-207.
• 29.
  Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discovery, 2005, 4(2): 145-160.
• 30.
  Hari S.K.; Gauba A.; Shrivastava N.; et al. Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system. Drug Delivery Transl. Res., 2023, 13(1): 135-163.
• 31.
  Brannon-Peppas L.; Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Delivery Rev., 2004, 56(11): 1649-1659.
• 32.
  Kale A.A.; Torchilin V.P. “Smart” drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J. Liposome Res., 2007, 17(3/4): 197-203.
• 33.
  Farokhzad O.C.; Langer R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3(1): 16-20.
• 34.
  Souza G.R.; Staquicini F.I.; Christianson D.R.; et al. Combinatorial targeting and nanotechnology applications. Biomed. Microdevices, 2010, 12(4): 597-606.
• 35.
  Juweid M.; Neumann R.; Paik C.; et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res., 1992, 52(19): 5144-5153.
• 36.
  Serda R.E.; Godin B.; Blanco E.; et al. Multi-stage delivery nano-particle systems for therapeutic applications. Biochim. Biophys. Acta, 2011, 1810(3): 317-329.
• 37.
  Godin B.; Serda R.E.; Liu X.W.; et al. Injectable multistage nanovectors for enhancing imaging contrast and directed therapy. Svenson, S.; Prud’homme, R.K. Multifunctional nanoparticles for drug delivery applications: nanostructure science and technology. Boston, MA: Springer, 2012: 201-223.
• 38.
  Souza G.R.; Christianson D.R.; Staquicini F.I.; et al. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents. Proc. Natl. Acad. Sci., 2006, 103(5): 1215-1220.
• 39.
  Sengupta S.; Eavarone D.; Capila I.; et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 2005, 436(7050): 568-572.
• 40.
  Chen A.M.; Zhang M.; Wei D.G.; et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small, 2009, 5(23): 2673-2677.
• 41.
  Tasciotti E.; Liu X.W.; Bhavane R.; et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol., 2008, 3(3): 151-157.
• 42.
  Khemtong C.; Kessinger C.W.; Ren J.M.; et al. In vivo off-resonance saturation magnetic resonance imaging of αvβ3-targeted superparamagnetic nanoparticles. Cancer Res., 2009, 69(4): 1651-1658.
• 43.
  Yoo H.S.; Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Controlled Release, 2004, 100(2): 247-256.
• 44.
  Jeong Y.I.; Seo S.J.; Park I.K.; et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(γ-benzyl l-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm., 2005, 296(1/2): 151-161.
• 45.
  Carpin L.B.; Bickford L.R.; Agollah G.; et al. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res. Treat., 2011, 125(1): 27-34.
• 46.
  Stoltenburg R.; Reinemann C.; Strehlitz B. SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng., 2007, 24(4): 381-403.
• 47.
  Thiviyanathan V.; Somasunderam A.D.; Gorenstein D.G. Combinatorial selection and delivery of thioaptamers. Biochem. Soc. Trans., 2007, 35(1): 50-52.
• 48.
  Röthlisberger P.; Hollenstein M. Aptamer chemistry. Adv. Drug Delivery Rev., 2018, 134: 3-21.
• 49.
  Esawi E.; Nsairat H.; Mahmoud I.S.; et al. 20 - Clinical use and future perspective of aptamers. Kesharwani P. Aptamers engineered nanocarriers for cancer therapy. Cambridge: Woodhead Publishing, 2023: 481-520.
• 50.
  Bai X.; Smith Z.L.; Wang Y.H.; et al. Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. Micromachines, 2022, 13(10): 1623.
• 51.
  Bagherifam S.; Skjeldal F.M.; Griffiths G.; et al. pH-responsive nano carriers for doxorubicin delivery. Pharm. Res., 2015, 32(4): 1249-1263.
• 52.
  Yu C.; Wang L.; Xu Z.Z.; et al. Smart micelles self-assembled from four-arm star polymers as potential drug carriers for pH-triggered DOX release. J. Polym. Res., 2020, 27(5): 111.
• 53.
  Bagheri M.; Shateri S.; Niknejad H.; et al. Thermosensitive biotinylated hydroxypropyl cellulose-based polymer micelles as a nano-carrier for cancer-targeted drug delivery. J. Polym. Res., 2014, 21(10): 567.
• 54.
  Wang J.J. Combination treatment of cervical cancer using folate-decorated, pH-sensitive, carboplatin and paclitaxel co-loaded lipid-polymer hybrid nanoparticles. Drug Des., Dev. Ther., 2020, 14: 823-832.
• 55.
  Guo S.J.; Vieweger M.; Zhang K.M.; et al. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nat. Commun., 2020, 11(1): 972.
• 56.
  Patil R.; Portilla-Arias J.; Ding H.; et al. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid). Pharm. Res., 2010, 27(11): 2317-2329.
• 57.
  Wang R.B.; Billone P.S.; Mullett W.M. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J. Nanomater., 2013, 2013: 629681.
• 58.
  Saif M.W. U.S. food and drug administration approves paclitaxel protein-bound particles (abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP. Journal of the Pancreas, 2013, 14(6): 686-688.
• 59.
  Martis E.; Badve R.; Degwekar M. Nanotechnology based devices and applications in medicine: an overview. Chron. Young Sci., 2012, 3(1): 68.
• 60.
  Anselmo A.C.; Mitragotri S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med., 2019, 4(3): e10143.
• 61.
  Pillai G. Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharmacy & Pharmaceutical Sciences, 2014, 1(2): 13.
• 62.
  Sharma G.; Sharma A.R.; Lee S.S.; et al. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int. J. Pharm., 2019, 559: 360-372.
• 63.
  Deo M.R.; Sant V.P.; Parekh S.R.; et al. Proliposome-based transdermal delivery of levonorgestrel. J. Biomater. Appl., 1997, 12(1): 77-88.
• 64.
  Li J.; Zhang Z.X.; Zhang B.L.; et al. Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. Biomater. Sci., 2023, in press.
• 65.
  Peters D.; Kastantin M.; Kotamraju V.R.; et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc. Natl. Acad. Sci., 2009, 106(24): 9815-9819.
• 66.
  Eniola-Adefeso O.; Heslinga M.J.; Porter T.M. Design of nano vectors for therapy and imaging of cardiovascular diseases. Methodist DeBakey Heart & Vascular Center, 2012, 8(1): 13-17.
• 67.
  Aikawa M.; Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc. Pathol., 2004, 13(3): 125-138.
• 68.
  Tölli M.A.; Ferreira M.P.A.; Kinnunen S.M.; et al. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. Biomaterials, 2014, 35(29): 8394-8405.
• 69.
  Pinchuk L.; Wilson G.J.; Barry J.J.; et al. Medical applications of poly(styrene-block-isobutylene-block-styrene) (“SIBS”). Biomaterials, 2008, 29(4): 448-460.
• 70.
  Tzafriri A.R.; Edelman E.R. Endovascular drug delivery and drug elution systems: first principles. Interventional Cardiol. Clin., 2016, 5(3): 307-320.
• 71.
  Karanasiou G.S.; Papafaklis M.I.; Conway C.; et al. Stents: biomechanics, biomaterials, and insights from computational modeling. Ann. Biomed. Eng., 2017, 45(4): 853-872.
• 72.
  Kleemann E.; Schmehl T.; Gessler T.; et al. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharm. Res., 2007, 24(2): 277-287.
• 73.
  Kan P.; Chen K.J.; Hsu C.F.; et al. Inhaled liposomal iloprost shows high drug encapsulation, extended release profile and potentials of improving patient compliance. Eur. Respir. J., 2018, 52: PA3038.
• 74.
  Rn K.; Gokhale P.C.; Kshirsagar N.A.; et al. Optimizing dosage regimens of liposomal amphotericin B using Aspergillus murine model. Indian J. Pharmacol., 1996, 28: 88.
• 75.
  Kshirsagar N.A.; Pandya S.K.; Kirodian G.B.; et al. Liposomal drug delivery system from laboratory to clinic. J. Postgrad. Med., 2005, 51(5): 5-15.
• 76.
  Tiwari G.; Tiwari R.; Sriwastawa B.; et al. Drug delivery systems: an updated review. Int. J. Pharm. Invest., 2012, 2(1): 2-11.
• 77.
  Sperry P.J.; Cua D.J.; Wetzel S.A.; et al. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med. Mycol., 1998, 36(3): 135-141.
• 78.
  Zhu Y.X.; Che L.; He H.M.; et al. Highly efficient nanomedicines assembled via polymer-drug multiple interactions: tissue-selective delivery carriers. J. Controlled Release, 2011, 152(2): 317-324.
• 79.
  Bummer P.M. Physical chemical considerations of lipid-based oral drug delivery—solid lipid nanoparticles. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2004, 21(1): 1-20.
• 80.
  Puoci F.; Iemma F.; Muzzalupo R.; et al. Spherical molecularly imprinted polymers (SMIPs) via a novel precipitation polymerization in the controlled delivery of sulfasalazine. Macromol. Biosci., 2004, 4(1): 22-26.
• 81.
  Priyam A.; Shivhare K.; Yadav S.; et al. Enhanced solubility and self-assembly of amphiphilic sulfasalazine-PEG-OMe (S-PEG) conjugate into core-shell nanostructures useful for colonic drug delivery. Colloids Surf., A, 2018, 547: 157-167.
• 82.
  Dhaneshwar S.S.; Gairola N.; Kandpal M.; et al. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. Eur. J. Med. Chem., 2009, 44(10): 3922-3929.
• 83.
  Li J.H.; Zhang Z.Z.; Li J.; et al. Copper-olsalazine metal-organic frameworks as a nanocatalyst and epigenetic modulator for efficient inhibition of colorectal cancer growth and metastasis. Acta Biomater., 2022, 152: 495-506.
• 84.
  Levine D.J. Runčevski T.; Kapelewski M.T.;et al. Olsalazine-based metal-organic frameworks as biocompatible platforms for H2 adsorption and drug delivery. J. Am. Chem. Soc., 2016, 138(32): 10143-10150.
• 85.
  Hakkou K.; Molina-Pinilla I.; Rangel-Núñez C.; et al. Synthesis of novel (bio) degradable linear azo polymers conjugated with olsalazine. Polym. Degrad. Stab., 2019, 167: 302-312.
• 86.
  Cortez-Maya S.; Pedro-Hernández L.D.; Martínez-Klimova E.; et al. Anticancer activity of water-soluble olsalazine-PAMAM-dendrimer-salicylic acid-conjugates. Biomolecules, 2019, 9(8): 360.
• 87.
  Mukhtar M.; Fényes E.; Bartos C.; et al. Chitosan biopolymer, its derivatives and potential applications in nano-therapeutics: a comprehensive review. Eur. Polym. J., 2021, 160: 110767.
• 88.
  Chaudhury A.; Das S. Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents. AAPS PharmSciTech, 2011, 12(1): 10-20.
• 89.
  Sonia T.A.; Sharma C.P. An overview of natural polymers for oral insulin delivery. Drug Discovery Today, 2012, 17(13/14): 784-792.
• 90.
  Sarmento B.; Ribeiro A.; Veiga F.; et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res., 2007, 24(12): 2198-2206.
• 91.
  Chiang W.L.; Ke C.J.; Liao Z.X.; et al. Pulsatile drug release from PLGA hollow microspheres by controlling the permeability of their walls with a magnetic field. Small, 2012, 8(23): 3584-3588.